Dasiglucagon

TRADE NAME: Zegalogue (Zealand Pharma)
INDICATIONS: Treatment of severe hypoglycemia in pediatric and adult patients with diabetes.
HALF-LIFE: ~30 minutes

FDA APPROVAL DATE: 03/22/2021
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
beta-blockers, Indomethacin, Warfarin
PREGNANCY: No available data on dasiglucagon use in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes.